Staley Capital Advisers Inc. Invests $581,000 in Standard BioTools Inc. $LAB

Staley Capital Advisers Inc. bought a new stake in Standard BioTools Inc. (NASDAQ:LAB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 632,392 shares of the company’s stock, valued at approximately $581,000. Staley Capital Advisers Inc. owned 0.16% of Standard BioTools at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Cibc World Markets Corp purchased a new stake in Standard BioTools during the 4th quarter worth $25,000. Aigen Investment Management LP purchased a new position in Standard BioTools in the fourth quarter valued at about $28,000. M&T Bank Corp purchased a new position in Standard BioTools in the fourth quarter valued at about $31,000. EntryPoint Capital LLC purchased a new position in Standard BioTools in the fourth quarter valued at about $31,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Standard BioTools by 2,989.0% during the third quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock worth $33,000 after purchasing an additional 24,211 shares in the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Price Performance

Shares of LAB stock opened at $0.88 on Thursday. The company’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.10. The firm has a market capitalization of $344.11 million, a P/E ratio of 4.41 and a beta of 1.42. Standard BioTools Inc. has a 12 month low of $0.70 and a 12 month high of $1.72.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings downgraded Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded Standard BioTools from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.